The Administrative Core provides the infrastructure for and coordinates all activities of the MPN Research Consortium (MPN-RC). Key functions include organizational management and communication, resource allocation and financial management (personnel, funds, equipment, and supplies), organization of all internal and external advisory boards and committees, scientific and clinical trials oversight to ensure regulatory compliance and procedural implementation, and external liaison to appropriate governmental agencies.
The specific aims of the Administrative Core are: 1) Coordinate the activities of all MPN-RC Projects and Cores and monitor progress in the Projects and effective use of shared resource Cores; 2) Schedule and provide optimal staff support for all MPN-RC committees and boards; 3) Assure that research involving the use of human subjects and vertebrate animals is pursued in compliance with NIH regulations; 4) Establish all contracts with participating organizations and administer and oversee all budgets and the disperal of funds; 5) Liaison to the NCI for all matters pertaining to the MPN-RC; 6) Develop and negotiate budgets and contracts with pharmaceutical companies to gain access to drugs for clinical trials to be pursued by Project 4; 7) Develop criteria for institutional membership in the MPN-RC and assist in membership applications and site initiation visits. In addition, monitor performance of all members to assure that they are optimally functioning in a fashion that merits their continued participation, 8) Prepare yearly progress reports to be submitted to the NCI. Orchestrate the resubmission of this competitive renewal application to the NCI.
|Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388|
|Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449|
|Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787|
|Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145|
|Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:|
|Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13|
|Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :|
|Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587|
|Migliaccio, Anna Rita; Varricchio, Lilian (2018) Concise Review: Advanced Cell Culture Models for Diamond Blackfan Anemia and Other Erythroid Disorders. Stem Cells 36:172-179|
|Ling, Te; Crispino, John D; Zingariello, Maria et al. (2018) GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy. Expert Rev Hematol 11:169-184|
Showing the most recent 10 out of 195 publications